Skip to main content

Table 3 Subgroup analysis for the association of VSR with the prevalence of MASLD according to sex

From: Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population

 

VSR

Q1

OR (95%CI)

Q2

OR (95%CI)

Q3

OR (95%CI)

Q4

OR (95%CI)

P for trend

P for interaction

Male

Age

     

0.011

 

18 ~ 44 yr

1.00 (ref.)

2.152 (1.606, 2.884) ***

3.145 (2.327, 4.252) ***

3.753 (2.717, 5.186) ***

< 0.001

 
 

45 ~ 59 yr

1.00 (ref.)

1.674 (1.344, 2.085) ***

2.531 (2.027, 3.159) ***

2.932 (2.333, 3.686) ***

< 0.001

 
 

≥ 60 yr

1.00 (ref.)

1.313 (0.838, 2.056)

2.115 (1.371, 3.262) **

3.161 (2.074, 4.819) ***

< 0.001

 
 

Current smoking

     

0.586

 

No

1.00 (ref.)

1.649 (1.344, 2.023) ***

2.817 (2.293, 3.461) ***

3.082 (2.493, 3.811) ***

< 0.001

 
 

Yes

1.00 (ref.)

1.920 (1.468, 2.510) ***

2.193 (1.674, 2.873) ***

3.285 (2.484, 4.345) ***

< 0.001

 
 

Current drinking

     

0.448

 

No

1.00 (ref.)

1.702 (1.412, 2.051) ***

2.839 (2.349, 3.433) ***

3.108 (2.559, 3.776) ***

< 0.001

 
 

Yes

1.00 (ref.)

1.867 (1.339, 2.602) ***

1.938 (1.403, 2.677) ***

3.145 (2.235, 4.426) ***

< 0.001

 
 

Exercise

     

0.548

 

No

1.00 (ref.)

1.784 (1.472, 2.163) ***

2.612 (2.156, 3.164) ***

3.366 (2.771, 4.089) ***

< 0.001

 
 

Yes

1.00 (ref.)

1.617 (1.192, 2.192) **

2.534 (1.844, 3.481) ***

2.426 (1.710, 3.441) ***

< 0.001

 
 

Central obesity

     

< 0.001

 

No

1.00 (ref.)

1.722 (1.452, 2.042) ***

2.398 (2.011, 2.859) ***

2.436 (2.021, 2.936) ***

< 0.001

 
 

Yes

1.00 (ref.)

1.153 (0.588, 2.261)

1.186 (0.645, 2.183)

1.864 (1.020, 3.049) *

< 0.001

 
 

Hyperhomocysteinemia

     

0.848

 

No

1.00 (ref.)

1.722 (1.455, 2.037) ***

2.515 (2.120, 2.983) ***

3.073 (2.575, 3.667) ***

< 0.001

 
 

Yes

1.00 (ref.)

2.113 (1.148, 3.890) *

3.311 (1.869, 5.864) ***

4.100 (2.309, 7.283) ***

< 0.001

 
 

Hyperuricemia

     

0.067

 

No

1.00 (ref.)

1.916 (1.592, 2.307) ***

2.852 (2.364, 3.441) ***

3.389 (2.792, 4.114) ***

< 0.001

 
 

Yes

1.00 (ref.)

1.308 (0.941, 1.820)

1.896 (1.364, 2.635) ***

2.717 (1.932, 3.821) ***

< 0.001

 

Female

Age

     

< 0.001

 

18 ~ 44 yr

1.00 (ref.)

1.335 (0.710, 2.510)

1.474 (0.801, 2.709)

3.760 (2.103, 6.720) ***

< 0.001

 
 

45 ~ 59 yr

1.00 (ref.)

0.981 (0.679, 1.417)

1.520 (1.083, 2.132) *

2.596 (1.871, 3.602) ***

< 0.001

 
 

≥ 60 yr

1.00 (ref.)

0.668 (0.403, 1.108)

0.786 (0.476, 1.299)

0.967 (0.625, 1.495)

0.117

 
 

Exercise

     

0.168

 

No

1.00 (ref.)

0.865 (0.651, 1.148)

1.147 (0.879, 1.496)

1.927 (1.502, 2.472) ***

< 0.001

 
 

Yes

1.00 (ref.)

2.322 (1.044, 5.163) *

3.597 (1.665, 7.772) **

4.323 (1.985, 9.419) ***

< 0.001

 
 

Central obesity

     

< 0.001

 

No

1.00 (ref.)

1.114 (0.765, 1.621)

1.365 (0.948, 1.966)

1.928 (1.321, 2.861) **

0.002

 
 

Yes

1.00 (ref.)

0.853 (0.549, 1.323)

0.830 (0.562, 1.226)

1.032 (0.726, 1.465)

0.048

 
 

Hyperuricemia

     

0.023

 

No

1.00 (ref.)

1.059 (0.816, 1.373)

1.369 (1.707, 1.752) *

2.441 (1.936, 3.078) ***

< 0.001

 
 

Yes

1.00 (ref.)

0.773 (0.139, 4.306)

0.763 (0.146, 3.984)

1.392 (0.299, 6.488)

0.216

 
  1. Note *P < 0.05, **P < 0.01, ***P < 0.001
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X